Abbott announced FDA clearance of the Advisor HD Grid Mapping Catheter, Sensor Enabled. Advisor HD Grid employs a new design...
Elekta has received 510(k) clearance from the FDA for the Versa HD radiation therapy system for cancer treatment. Versa HD...
Neurocrine Biosciences announced positive top-line data from its Phase III KINECT-HD study evaluating the efficacy, safety and tolerability of valbenazine , a selective vesicular monoamine transporter 2 (VMAT2) inhibitor being investigated as a once-daily treatment in adults with chorea associated with Huntington disease (HD).
Prilenia Therapeutics announced preliminary topline results of its Phase III PROOF-HD clinical study evaluating the safety and efficacy of pridopidine in individuals with Huntington’s disease (HD)
Background: TRACK-HD is a prospective observational biomarker study in premanifest and early Huntington's disease (HD). In this report we define...
Regeneron Pharmaceuticals, Inc. announced that the FDA has approved Eylea HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR).
Neurocrine Biosciences, Inc. announced that the complete study results from its Phase III KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington's disease (HD) has been published in The Lancet Neurology online edition and will appear in the June 2023 print issue.
HD LifeSciences has received FDA 510(k) clearance for its Hive ALIF standalone lumbar interbody fusion system, an adjustable spinal implant. The implant technology enables surgeons to choose between integrated zero-profile fixation or anterior plating and can be adjusted prior to implantation to better fit patient anatomy. The Hive ALIF system offers surgeons a number of configurations for height, width, depth and lordotic choices.
Active Biotech provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical Industries Ltd. The Phase II LEGATO-HD...
Neurocrine Biosciences, Inc. announced results from the Phase III KINECT-HD study, which demonstrated once-daily administration of valbenazine was associated with significant improvement in chorea associated with Huntington disease (HD) compared with placebo.